TY  - GEN
AU  - Meulendijks,Didier
AU  - Lassen,Ulrik N
AU  - Siu,Lillian L
AU  - Huitema,Alwin D R
AU  - Karanikas,Vaios
AU  - Mau-Sorensen,Morten
AU  - Jonker,Derek J
AU  - Hansen,Aaron R
AU  - Simcox,Mary E
AU  - Schostack,Kathleen J
AU  - Bottino,Dean
AU  - Zhong,Hua
AU  - Roessler,Markus
AU  - Vega-Harring,Suzana M
AU  - Jarutat,Tiantom
AU  - Geho,David
AU  - Wang,Karen
AU  - DeMario,Mark
AU  - Goss,Glenwood D
AU  - Schellens,Jan H M
TI  - Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
SN  - 1557-3265
PY  - 2016///1103
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - pharmacokinetics
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - blood
KW  - Chemokine CCL2
KW  - Colorectal Neoplasms
KW  - Cytokine TWEAK
KW  - Female
KW  - Gene Expression
KW  - Humans
KW  - Male
KW  - Matrix Metalloproteinase 9
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Receptors, Tumor Necrosis Factor
KW  - TNF Receptor-Associated Factor 1
KW  - metabolism
KW  - TWEAK Receptor
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor Inhibitors
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-15-1506
ER  -